Edition:
United States

Bristol-Myers Squibb Co (BMYMP.PK)

BMYMP.PK on OTC Markets Group

985.00USD
1:49pm EDT
Change (% chg)

$0.00 (+0.00%)
Prev Close
$985.00
Open
$985.00
Day's High
$985.00
Day's Low
$985.00
Volume
20
Avg. Vol
20
52-wk High
$1,231.90
52-wk Low
$985.00

BMYMP.PK

Chart for BMYMP.PK

About

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small... (more)

Overall

Beta: 0.72
Market Cap(Mil.): $92,047.59
Shares Outstanding(Mil.): 1,670.86
Dividend: 0.38
Yield (%): 2.76

Financials

  BMYMP.PK Industry Sector
P/E (TTM): 32.24 37.66 37.54
EPS (TTM): 1.71 -- --
ROI: 11.95 14.54 13.98
ROE: 19.11 15.32 14.88

Bristol-Myers to test Opdivo with Nektar drug for several cancers

Bristol-Myers Squibb Co said on Tuesday it would evaluate the use of its blockbuster cancer immunotherapy Opdivo in combination with an experimental drug from Nektar Therapeutics to treat multiple cancers.

Sep 27 2016

BRIEF-Bristol-Myers Squibb and Nektar Therapeutics announce Oncology clinical collaboration

* Myers Squibb and Nektar Therapeutics announce Oncology clinical collaboration to evaluate combination of Opdivo (nivolumab) and NKTR-214

Sep 27 2016

Hard to swallow: emerging markets get tougher for drugmakers

LONDON Emerging markets have lost their luster for Big Pharma making drug firms ever more dependent on the United States for growth just as American anger over high medicine prices is building.

Sep 22 2016

BRIEF-Bristol-Myers says EMA validates type II variation application for Opdivo

* European Medicines Agency validates Bristol Myers Squibb's type II variation application for Opdivo (nivolumab) in advanced form of bladder cancer

Sep 20 2016

New Mexico AG sues Bristol-Myers, Sanofi over blood thinner

New Mexico Attorney General Hector Balderas has sued Bristol-Myers Squibb Co and Sanofi SA's U.S. arm for overstating the effectiveness of and concealing the risks of their blood thinner Plavix.

Sep 16 2016

BRIEF-European Commission approves Bristol-Myers Squibb's Orencia (Abatacept)

* Myers Squibb's Orencia (Abatacept) for the treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with Methotrexate

Sep 06 2016

BRIEF-Aveo initiates evaluation of Tivozanib in combination with Bristol-Myers Squibb's opdivo in advanced renal cell carcinoma

* Initiates Evaluation Of Tivozanib In Combination With Bristol Myers Squibb's Opdivo (nivolumab) in advanced renal cell carcinoma

Aug 15 2016

Bristol-Myers' Opdivo fails lung cancer trial; shares plunge

Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's rival medicine.

Aug 05 2016

UPDATE 4-Bristol-Myers' Opdivo fails lung cancer trial; shares plunge

Aug 5 Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit Merck & Co's rival medicine.

Aug 05 2016

BRIEF-Moody's says Bristol-Myers Squibb's lung cancer trial result a major setback

* Moody's: Bristol's lung cancer trial result a major setback

Aug 05 2016

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $117.64 -1.75
Pfizer Inc. (PFE.N) $33.51 -0.49
Merck & Co., Inc. (MRK.N) $62.04 -1.26
Sanofi SA (SASY.PA) €68.03 -0.29
AstraZeneca plc (AZN.L) 5,026.00p -96.00
GlaxoSmithKline plc (GSK.L) 1,647.50p -7.50
Eli Lilly and Co (LLY.N) $79.85 -0.86
Roche Holding Ltd. (ROG.S) CHF241.80 -2.80
Roche Holding Ltd. (RO.S) CHF242.90 -2.00

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : New Constructs, LLC
$25.00
Provider : Stock Traders Daily
$20.00
Provider : Wright Reports
$75.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.